

Pidilizumab Biosimilar - Research Grade

Product Code: ICH5773

More Information

Species Reactivity: Human

Target: PDCD1

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Pidilizumab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q15116

Shipping Conditions: Blue ice

background: PDCD1 (PD-1) is an inhibitory T-cell checkpoint receptor at the heart of immuno-oncology research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of pidilizumab, expressed in CHO cells against human PDCD1. Released for research use only, it is formulated to low endotoxin for in vivo suitability and manufactured in scalable milligram (mg) to gram (g) quantities for high-throughput, heavy-usage laboratories. It is a reliable reagent for checkpoint-blockade functional assays, T-cell activation studies, ADCC investigations, and preclinical tumor-immunity models. Predictable performance across batches helps standardize multi-arm experimental designs.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks